A Prospective Multi-Site Observational Study of SARS-CoV-2 Vaccination Immunogenicity in Patients with Hematologic Malignancies [VIP, study data contributed to the CITF Databank]

Aims of the CITF-funded study: This study aimed to quantify the humoral immune response to the SARS-CoV-2 vaccine and to describe Grade 2-4 adverse events following immunization in patients with hematologic malignancies.

Methods

This cohort study enrolled patients with hematologic malignancies aged 18 and older from hematology clinics in participating hospitals in Edmonton, Montreal, Ottawa, and Toronto. Participants completed an online questionnaire and provided a dried blood spot sample at baseline and during each follow-up—approximately 90, 180, 270, and 360 days after their second COVID-19 vaccine. Blood samples were also collected 28 days after any additional COVID-19 vaccination dose.

Contributed dataset contents: The datasets include 751 participants who completed baseline questionnaires between August 2021 and August 2023. 95% of participants gave one or more blood samples for SARS-CoV-2 serology between September 2021 and February 2023. Variables include data in the following areas of information: demographics (age, gender, race-ethnicity and indigeneity, region, education, occupation), general health (smokes; chronic disease; height and weight; flu vaccine), SARS-CoV-2 vaccination, clinical characteristics, and serology.